AstraZeneca Reports Phase 3 FLAURA Results for Tagrisso in First-Line EGFR-Mutated NSCLC

AstraZeneca today announced results from the Phase 3 FLAURA trial evaluating Tagrisso (osimertinib) versus erlotinib or gefitinib as first-line treatment for EGFR-mutated non-small cell lung cancer. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with Tagrisso. The risk of disease progression or death was reduced by 54%.